Hims & Hers Health shares fell 12% in after-hours trading on Monday after the telehealth company missed second-quarter revenue and earnings expectations, according to Barron's. The platform reported earnings of 17 cents per share and $544.8 million in revenue, up over 72% from last year but below the $551.7 million expected by analysts. Guidance for third-quarter revenue was in line at $570 million to $590 million, and full-year 2025 targets remained unchanged. CEO Andrew Dudum said Hims & Hers is entering a growth phase by expanding into new specialties. The company said it’s expanding into new care categories beyond its current offerings in weight loss, sexual health, hair loss, and mental health. Concerns remain about future demand now that the shortage of GLP-1 drugs, like Wegovy, has ended.
Be the first to comment